All In MedTech

Device Trial Radar · NCT06472245

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

363

Planned (sponsor's estimate)

Start

Dec 3, 2024

Primary completion

May 1, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
OSE ImmunotherapeuticsNot on our public-company list
Sponsor type
Industry
Collaborators
Exystat; GeneDx
First posted
Jun 25, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Conditions

  • Patients With Non-Small Cell Lung Cancer

Interventions

  • OSE2101Drug

    OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.

  • DocetaxelDrug

    Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.

  • NGS HLAA2 assayDevice

    Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OS defined as time from randomization to deathTime frame: From randomization date through study completion, an average of 3 years

Locations

207 sites in 14 countries. Site status is shown where the registry gives one.

  • Clinical Research Advisors, LLC

    Beverly Hills, California · Recruiting

  • Clinical Research Advisors - Encino

    Encino, California · Active not recruiting

  • Clinical Research Advisors - West Hollywood

    Los Angeles, California · Active not recruiting

204 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.